Biopharma
The latest news about Biopharma: headlines, AI summaries and the full story from every source.
- Nuvation Bio Reports Third Quarter Revenue of $45 Million, Exceeding Estimates
- Alnylam Pharmaceuticals Shares Drop 18% Despite Q3 Earnings Beat Due to Slowing US Sales
- Haemonetics Gains After Update on CSL Supply Deal
- Viking Therapeutics Shares Surge After Positive Clinical Trial Results for Obesity Drug
- BofA Upgrades Candel Therapeutics Following Positive Outlook for Prostate Cancer Gene Therapy
- Cue Biopharma Shares Drop Over 30% Following Disappointing Phase 2 Trial Results for Chronic Spontaneous Urticaria Treatment
- Cue Biopharma Shares Rise Sharply in Premarket Trading After Positive Phase 2 Trial Results
- Chinese Biopharma Stocks Rise as US Signals Openness to Drug Licensing Deals
- Chinese Biopharma Stocks Rise Amid U.S. Consideration of Continued Drug Licensing Deals
- U.S. Considers Allowing Most Pharma Licensing Deals With China
- Labcorp Outlines Growth Strategy Focused on AI and Specialty Testing Through 2029
- Novartis' Pelacarsen Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Ambit Acquired by Danforth Health with Advisory Support from Clearsight Advisors
- argenx Acquires Forte Biosciences for $2.2 Billion in Cash
- Grifols Reports Q2 2026 Earnings with Strong Biopharma and IG Franchise Growth
- Argenx Acquires Forte Biosciences for $2.2 Billion
- Vertex Pharmaceuticals Acquires Crinetics in $10 Billion Deal at High Premium
- French VC Fundraising Rebounds but Remains Concentrated
- Kalshi Launches Prediction Markets for Biopharma Clinical Trials and Drug Approvals
- ARS Pharmaceuticals Appoints Donn Casale As New CEO
- AEON Biopharma Prices $13.75 Million Offering with Milestone Warrants
- Nuvation Bio's Stock Potential Amid Regulatory Progress
- Theravance Biopharma Downgraded by Jones Trading Following Zymeworks Acquisition
- Grifols Launches FESILTY for Congenital Fibrinogen Deficiency Treatment
- AbbVie Beats Revenue Estimates and Raises Guidance, Strengthening Dividend Outlook
- Summit Therapeutics Reveals Positive Phase II Trial Data for Ivonescimab
- Eli Lilly Expands Innovation Through Biopharma Collaborations
- Grifols Reports Strong Biopharma Growth Driven by Gamunex and Yimmugo
- Travere Therapeutics Enters Licensing Agreement Worth up to $1.1 Billion with Everest Medicines
- Immix Biopharma Completes $150 Million Stock Offering
- Merck's Lung Cancer Combo Outperforms Keytruda in Late-Stage Trial
- Immix Biopharma Reports Mid-Stage Trial Data for AL Amyloidosis Therapy
- Immix Biopharma Reports 95% Complete Response Rate in Relapsed/Refractory AL Amyloidosis Trial
- Parabilis Medicines Files U.S. IPO Filing After Research Pact With Regeneron
- SandboxAQ Integrates Drug Discovery Models into Anthropic's Claude
- Octagon Capital Advisors Acquires $22.58 Million Stake in Xenon Pharmaceuticals Ahead of FDA Filing
- Citizens Raises Price Target for Sutro Biopharma (STRO) Due to Strong Pipeline and Lead Program
- Thermo Fisher to Sell Microbiology Business to Astorg in $1 Billion Deal
- Sagimet Biosciences Announces U.S. Phase 3 Trials for Acne Treatment Denifanstat
- Sagimet Biosciences Announces U.S. Phase 3 Trials for Acne Drug Denifanstat
- Cue Biopharma Appoints Lucinda Warren as Interim President and CEO
- Citi Increases Price Target for Gilead Sciences Ahead of Q1 Biopharma Outlook